Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Grace Therapeutics, Inc. (GRCE : NSDQ)

• Company Description    Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey. Number of Employees: 6

• Price / Volume Information    Yesterday's Closing Price: $3.10 Daily Weekly Monthly 20 Day Moving Average: 49,386 shares Shares Outstanding: 13.83 (millions) Market Capitalization: $42.87 (millions) Beta: 0.92 52 Week High: $4.97 52 Week Low: $1.75 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 6.16% 2.19% 12 Week 48.33% 24.76% Year To Date -17.11% -22.38%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 103 CARNEGIE CENTER SUITE 300 - PRINCETON,NJ 08540 CAN ph: 609-322-1602 fax: 45-0687-2272 acst@crescendo-ir.com http://www.acastipharma.com

• General Corporate Information    Officers Prashant Kohli - Chief Executive Officer Robert DelAversano - Principal Financial Officer Brian Davis - Director Vimal Kavuru - Director Edward Neugeboren - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00439U104 SIC: 2834 Fiscal Year Fiscal Year End: March Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/08/25 Share - Related Items Shares Outstanding: 13.83 Most Recent Split Date: 7.00 (0.17:1) Beta: 0.92 Market Capitalization: $42.87 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.82 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.64 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -16.67% vs. Previous Quarter: 19.23% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -19.45 12/31/24 - -20.10 ROA 06/30/25 - - 03/31/25 - -16.99 12/31/24 - -17.10 Current Ratio 06/30/25 - - 03/31/25 - 11.77 12/31/24 - 6.06 Quick Ratio 06/30/25 - - 03/31/25 - 11.77 12/31/24 - 6.06 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 4.86 12/31/24 - 5.14 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©